Loading...

Evgen Pharma plc

EVG.LLSE
Healthcare
Biotechnology
£0.82
£0.02(2.25%)

Evgen Pharma plc (EVG.L) Company Profile & Overview

Explore Evgen Pharma plc’s business operations, leadership, sector classification, and key company facts including IPO date, industry, and contact details.

Evgen Pharma plc (EVG.L) Company Profile & Overview

Evgen Pharma plc, a clinical stage drug development company, focuses on the development of sulforaphane-based medicines for the treatment of cancer and inflammatory diseases. It develops its products using Sulforadex, a sulforaphane stabilization technology. The company's lead product is SFX-01, that is in Phase II clinical trials for the treatment of metastatic breast cancer; and in Phase Ib/IIa clinical trials for the treatment of glioblastoma, as well as in preclinical stage for the treatment of haematological malignancies and analogues. It also provides out-licensing of its technology services. Evgen Pharma plc was incorporated in 2014 and is headquartered in Nether Alderley, the United Kingdom.

SectorHealthcare
IndustryBiotechnology
CEODr. Huw Jones BSc, Ph.D.

Contact Information

44 16 2546 6591
Alderley Park, Block 24, Nether Alderley, SK10 4TG

Company Facts

10 Employees
IPO DateOct 21, 2015
CountryGB

Frequently Asked Questions